These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 9333042)

  • 1. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP; Andrews J; Wise R
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN; Hryniewicz W
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
    Biavasco F; Lupidi R; Varaldo PE
    Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
    Kirk M; Hill RL; Casewell MW; Beighton D
    Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
    García-Garrote F; Cercenado E; Alcalá L; Bouza E
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2452-5. PubMed ID: 9736584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
    Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
    Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
    Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
    Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
    Johnson AP; Uttley AH; Woodford N; George RC
    Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
    Jones RN; Barrett MS; Erwin ME
    Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
    al-Nawas B; Shah PM
    Infection; 1998; 26(3):165-7. PubMed ID: 9646108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.